Autologous peripheral blood stem cell transplantation for acute leukaemias

Bailliere's Best Practice in Clinical Haematology

Volumn 12, Issue 1-2, 1999, Pages 139-150

  De La Rubia, Javier ^a   Sanz, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Acute myeloblastic leukaemia; Autologous blood stem cell transplant; Peripheral blood stem cell

Indexed keywords

CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ACUTE LEUKEMIA; AUTOGRAFT; BONE MARROW TRANSPLANTATION; CHEMOTHERAPY; CONTAMINATION; DRUG MEGADOSE; HEMATOPOIESIS; HUMAN; MYELOID LEUKEMIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; STEM CELL TRANSPLANTATION; SURVIVAL;

EID: 0032709671     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0013     Document Type: Article

References (50)

1. To LB, Haylock DN, Kimber RJ & Juttner CA. High levels of circulating haemopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. British Journal of Haematology 1984; 58: 399-410.
2. Juttner CA, To LB, Haylock DN et al. Circulating autologous stem cells in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. British Journal of Haematology 1985; 61: 739-745.
3. Reiffers J, Bernard P, David P et al. Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukaemia. Experimental Haematology 14: 312-315.
4. Castaigne S, Calvo F, Douay L et al. Successful haematopoietic reconstitution using autologous peripheral blood mononucleated cells in a patient with acute promyelocytic leukaemia. British Journal of Haematology 1986; 63: 209-211.
5. Tilly H, Bastit D, Lucet JC et al. Haemopoietic reconstitution after autologous peripheral blood stem cell transplantation in acute leukaemia. Lancet 1986; i: 154-155.
6. Szer J, Juttner CA, To LB et al. Post-remission therapy for acute myeloid leukemia with blood-derived stem cell transplantation. Results of a collaborative phase II trial. International Journal of Cell Cloning 1992; 10 (supplement 1): 114-116.
7. Reiffers J, Körbling M, Labopin M et al. Autologous blood stem cell transplantation versus autologous bone marrow transplantation for acute myeloid leukemia in first complete remission. International Journal of Cell Cloning 1992; 10 (supplement 1): 111-113.
8. Körbling M, Fliedner TM, Holle R et al. Autologous blood stem cell (ABSCT) versus purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplantation 1991; 7: 343-349.
9. Sanz MA, de la Rubia J, Sanz GF et al. Busulfan plus cyclophosphamide followed by autologous blood stem-cell transplantation for patients with acute myeloblastic leukemia in first complete remission: a report from a single institution. Journal of Clinical Oncology 1993; 11: 1661-1667.
10. Schiller G, Miller T, Lee M et al. Transplantation of autologous peripheral blood progenitor cells procured after high-dose cytarabine/G-CSF-based consolidation for adults with acute myelogenous leukemia in first complete remission. Blood 1996; 88 (supplement 1): 127a.
11. Linker CA, Ries CA, Damon LE et al. Autologous stem cell transplantation for acute myeloid leukemia in first remission. Blood 1997; 90 (supplement 1): 113a.
12. Reichle A, Hennemann B, Meidenbauer N et al. Peripheral blood stem cell transplantation (PBSCT) during consolidation treatment of de novo acute myelogenous leukemia. Bone Marrow Transplantation 1997; 19 (supplement 1): 396a.
13. Martin C, Torres A, Léon A et al. Autologous peripheral blood stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome. Bone Marrow Transplantation 1998; 21: 375-382.
14. De la Rubia J, Sanz GF, Martin G et al. Autologous blood stem cell transplantation (ABSCT) for acute myeloblastic leukemia in first remission. Intensification therapy before transplant does not prolong disease-free survival. Haematologica 84: 125-132.
15. Gondo H, Harada M, Miyamoto T et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia. Bone Marrow Transplantation 1997; 20: 821-826.
16. Löwenberg B, Verdonck LJ, Dekker AW et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. Journal of Clinical Oncology 1990; 8: 287-294.
17. Sierra J, Brunet S, Grañena A et al. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Journal of Clinical Oncology 1996; 14: 1353-1363.
18. Reiffers J, Labopin M, Sanz MA et al. The source of stem cells does not affect the outcome of patients undergoing autologous stem cell transplantation for acute myeloid leukemia in first remission. Blood 1996; 88 (supplement 1): 684a.
19. Harousseau JL, Cahn JY, Pignon B et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. Blood 1997; 90: 2978-2986.
20. Burnett AK, Goldstone AH, Stevens R et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. Lancet 1998; 351: 700-708.
21. Körbling M, Hunstein W, Fliedner TM et al. Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia. Blood 1989; 74: 1898-1904.
22. Laporte JP, Douay L, Lopez M et al. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. Blood 1994; 84: 3810-3818.
23. Mehta J, Powles R, Singhal S & Treleaven J. Peripheral blood stem cell transplantation may result in increased relapse of acute myeloid leukemia due to reinfusion of a higher number of malignant cells. Bone Marrow Transplantation 1995; 15: 652-653.
24. Stein AS, O'Donnell MR, Chai A et al. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukaemia in first complete remission. Journal of Clinical Oncology 1996; 14: 2206-2216.
25. Miggiano MC, Gherlinzoni F, Rosti G et al. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia. Leukemia 1996; 10: 402-409.
26. Pendry K, Alcorn MJ & Burnett AK. Factors influencing haematological recovery in 53 patients with acute myeloid leukaemia in first remission after autologous bone marrow transplantation. British Journal of Haematology 1993; 83: 45-52.
27. Zittoun RA, Mandelli F, Willemze R et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. New England Journal of Medicine 1995; 332: 217-223.
28. Arlin ZA, Fried J & Clarkson BD. Therapeutic role of cell kinetics in acute leukaemia. Clinical Haematology 1978; 7: 339-362.
29. To LB & Juttner CA. Peripheral blood stem cell autografting - a new therapeutic option for ANLL? British Journal of Haematology 1987; 66: 285-289.
30. To LB, Russell J, Moore S & Juttner CA. Residual leukemia cannot be detected in very early remission peripheral blood stem cell collections in acute non-lymphoblastic leukemia. Leukemia Research 1987; 11: 327-330.
31. Laporte JP, Gorin NC, Feuchtenbaum J et al. Relapse after autografting with peripheral blood stem cells. Lancet 1987; ii: 1393.
32. Moos M, Schmohl D, Fischer K et al. Prospective monitoring of minimal residual disease by polymerase chain reaction in patients with acute myeloid leukemia expressing CBFb/MYHII fusion transcripts. Blood 1996; 88 (supplement 1): 562a.
33. Miyamoto T, Nagafuji K, Harada M & Niho Y. Significance of quantitative analysis of AMLI/ETO transcripts in peripheral blood stem cells from t(8;21) acute myelogenous leukemia. Leukemia Lymphoma 1997; 21: 69-75.
34. Gale R & Champlin R. How does bone-marrow transplantation cure leukaemia? Lancet 1984; i: 28-29.
35. Reiffers J, Stoppa AM, Attal M & Michallet M. Is there a place for blood stem cell transplantation for the younger adult patient with acute myelogenous leukemia? Journal of Clinical Oncology 1994; 12: 1100-1101.
36. Reiffers J. Incidence of relapse following blood stem cell transplantation for acute myeloid leukemia in first remission. Bone Marrow Transplantation 1996; 16: 899-901.
37. Reiffers J, Marit G, Rice A et al. Peripheral blood stem cell transplantation in patients with acute myeloid leukaemia. In Dicke KA, Armitage JO, Dicke-Evinger MJ (eds). Autologous Bone Marrow Transplantation, pp 823-837. Proceedings of the Fifth International Symposium, 1991. Omaha, Nebraska: University of Nebraska.
38. Demirer T, Petersen FB, Bensinger WI et al. Autologous transplantation with peripheral blood stem cells collected after colony-stimulating factor in patients with acute myelogenous leukemia. Bone Marrow Transplantation 1996; 18: 29-34.
39. Haas R, Möhle R, Frühauf S et al. Patient characteristics associated with successful mobilizing cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
40. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. Journal of Clinical Oncology 1995; 13: 2547-2555.
41. Löwenberg B & Voogt P (1986). Autologous stem cell transplantation and purging. Journal of Clinical Oncology 1986; 14: 2194-2196.
42. Carlo-Stella C, Tabilio A, Regazzi E et al. Effect of chemotherapy for acute myelogenous leukemia on hematopoietic and fibroblast marrow progenitors. Bone Marrow Transplantation 1997; 20: 465-471.
43. Bender JG, To LB, Williams S & Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. Journal of Hematotherapy 1992; 1: 329-342.
44. Schlenk RF, Döhner H, Pförisch M et al. Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukaemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone. British Journal of Haematology 1997; 99: 386-393.
45. Jowitt SN, Chang J, Morgenstern GR et al. Factors which affect the CFU-GM content of the peripheral blood haemopoietic progenitor cell harvests in patients with acute myeloid leukaemia. British Journal of Haematology 1998; 100: 688-694.
46. Botnick LE, Hannon EC, Vigneulle R & Hellman S. Differential effects of cytotoxic agents on haematopoietic progenitors. Cancer Research 1981; 41: 2338-2344.
47. Meloni G, De Fabritiis P, Petti MC & Mandelli F. BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. Blood 1990; 75: 2282-2285.
48. Meloni G, Vignetti M, Avvisati G et al. BAVC regimen and autograft for patients with acute myelogenous leukemia in second remission. Bone Marrow Transplantation 1996; 18: 693-698.
49. De la Rubia J, Sanz GF, Martin G et al. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation. Bone Marrow Transplantation 1996; 18: 1167-1173.
50. Ferrant M, Labopin M, Frassoni F et al. Karyotype in acute myeloblastic leukemia: Prognostic significance of bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Blood 1997; 90: 2931-2938.